Cargando…

Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials

IMPORTANCE: Erythrodermic atopic dermatitis (AD) is a severe AD subtype defined by extensive skin involvement, leading to complications and sometimes hospitalization. OBJECTIVE: To assess dupilumab’s efficacy and safety in patients with erythrodermic AD in clinical trials. DESIGN, SETTING, AND PARTI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paller, Amy S., Silverberg, Jonathan I., Cork, Michael J., Guttman-Yassky, Emma, Lockshin, Benjamin, Irvine, Alan D., Kim, Moon Bum, Kabashima, Kenji, Chen, Zhen, Lu, Yufang, Bansal, Ashish, Rossi, Ana B., Shabbir, Arsalan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018319/ https://www.ncbi.nlm.nih.gov/pubmed/36723913 http://dx.doi.org/10.1001/jamadermatol.2022.6192

Ejemplares similares

Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial
por: Paller, Amy S., et al.
Publicado: (2019)

Recalcitrant erythrodermic ichthyosis with atopic dermatitis successfully treated with Dupilumab in combination with Guselkumab
por: Steinhoff, M., et al.
Publicado: (2021)

Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey‐based position statement
por: Leshem, Y.A., et al.
Publicado: (2019)

Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

A case report of uveitis secondary to dupilumab treatment for atopic dermatitis
por: Ayasse, Marissa, et al.
Publicado: (2020)

Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
por: Bansal, Ashish, et al.
Publicado: (2021)

Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis
por: Paller, Amy S., et al.
Publicado: (2022)

Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion
por: Thyssen, J.P., et al.
Publicado: (2019)

The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis
por: Kamal, Mohamed A., et al.
Publicado: (2021)

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial
por: Simpson, Eric L., et al.
Publicado: (2019)

Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis—A pooled analysis of trial data
por: Paller, Amy S., et al.
Publicado: (2022)

Dupilumab for atopic dermatitis
Publicado: (2019)

Tape-Strip Proteomic Profiling of Atopic Dermatitis on Dupilumab Identifies Minimally Invasive Biomarkers
por: He, Helen, et al.
Publicado: (2020)

Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Erythrodermic atopic dermatitis with late onset–case presentation
por: Lancrajan, C, et al.
Publicado: (2010)

Changes in Skin and Nasal Microbiome and Staphylococcal Species Following Treatment of Atopic Dermatitis with Dupilumab
por: Olesen, Caroline Meyer, et al.
Publicado: (2021)

Successful Treatment of Erythrodermic Atopic Dermatitis with Dupilumab in a 5-Year-Old Girl: A Case Report with Review of Literature
por: Agarwal, Akash, et al.
Publicado: (2022)

Severe atopic dermatitis and dupilumab
por: Bernardo, Wanderley, et al.
Publicado: (2023)

Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis
por: WOLLENBERG, Andreas, et al.
Publicado: (2022)

Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
por: Gelato, Federica, et al.
Publicado: (2023)

A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy
por: Paller, A.S., et al.
Publicado: (2020)

COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab
por: Ungar, Benjamin, et al.
Publicado: (2022)

Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records Dataset
por: Eichenfield, Lawrence F., et al.
Publicado: (2022)

Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older
por: Simpson, Eric L., et al.
Publicado: (2021)

IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis
por: Callewaert, Chris, et al.
Publicado: (2019)

Laboratory Safety of Dupilumab in Patients Aged 6–11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial
por: Paller, Amy S., et al.
Publicado: (2021)

Successful use of ustekinumab therapy in refractory severe atopic dermatitis
por: Shroff, Anjali, et al.
Publicado: (2014)

Nomenclature and clinical phenotypes of atopic dermatitis
por: Girolomoni, Giampiero, et al.
Publicado: (2021)

Erythrodermic presentation of psoriasis in a patient treated with dupilumab
por: Tracey, Elisabeth H., et al.
Publicado: (2018)

Nonbullous erythrodermic pemphigoid with florid lymphadenopathy, response to dupilumab
por: Bal, Arjun, et al.
Publicado: (2021)

Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement
por: Drucker, A.M., et al.
Publicado: (2018)

Alopecia areata after dupilumab for atopic dermatitis
por: Mitchell, Krystal, et al.
Publicado: (2018)

Conjunctivitis in patients with atopic dermatitis treated with dupilumab
por: Ferreira, Sandra, et al.
Publicado: (2020)

Onychodystrophy associated with dupilumab therapy for atopic dermatitis
por: Zubek, Amanda E., et al.
Publicado: (2020)

Practical Management of Patients with Atopic Dermatitis on Dupilumab
por: Papp, Kim A., et al.
Publicado: (2021)

Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective
por: de Bruin-Weller, Marjolein, et al.
Publicado: (2021)

Improvement of atopic dermatitis and alopecia universalis with dupilumab
por: Alotaibi, Lama, et al.
Publicado: (2021)

Dupilumab in the Treatment of Cheilitis in Atopic Dermatitis Patients
por: Shan, Jinpeng, et al.
Publicado: (2022)

Priority research questions in atopic dermatitis: an International Eczema Council eDelphi consensus
por: Abuabara, K., et al.
Publicado: (2021)

Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics
por: Mansouri, Yasaman, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_a2b64deu49o15lm2ci7rj1mgun